Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

873P - Early efficacy prediction of nasopharyngeal carcinoma based on 3D-ADC acquired during radiotherapy: A phase II prospective study

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Head and Neck Cancers

Presenters

Mei Feng

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

M. Feng1, L. Yan2, X. Du1, H. Wang3, J. Ren1, M. Wang1, Q. Yin1, X. Lai1, L. Li1, M. Lan1, S. Lu1, Y. Huang4, F. Li1, X. Xu5, W. Wang1, J. Lang1

Author affiliations

  • 1 Radiation Oncology, Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,, 610041 - Chengdu/CN
  • 2 Radiation Oncology, Chengdu Medical College, 610041 - Chengdu/CN
  • 3 Radiation Oncology, Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,, 610041 - Chengdu/CL
  • 4 Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 610000 - Chengdu/CN
  • 5 Information And Software Engineering, Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 873P

Background

Concurrent chemoradiotherapy (CCRT) is the main treatment model for locally advanced nasopharyngeal carcinoma. Previous study found the apparent diffusion coefficient (ADC) value of primary tumor partly correlated to prognosis for NPC patients. We aimed to observe the dynamic changes of ADC of gross target volume (GTV) and metastatic lymph nodes (LN) for NPC patients during radiotherapy (RT), and explored the potential correlations between ADC changes and treatment response.

Methods

50 squamous NPC (II-IVa) patients treated with definitive RT were enrolled in this study. The patients received DWI scan at pre-RT, the 5th and 15th fractions and immediately post-RT on a 3.0T MRI system. The ADC values of GTV and LN were acquired using MIM software. RECIST1.1 criteria were used to evaluate the tumor response. Multivariate analyses were calculated using the logistic regression model. Receiver-operating characteristic (ROC) curve was used to determine the cut-off value of ADC.

Results

After the completion of CCRT, the ORR for all the patients was 100% (CR 58%, PR 42%). The mean ADC value of GTV and LN gradually increased from pre-RT to post RT. These changes generally occurred in two stages. For the first stage (from pre-RT to the 5th fraction), the mean ADC value of GTV and LN increased significantly by 20.78% and 22.96% respectively, while the volumes of GTV and LN had minimal changes (GTV:18.42cm3 vs 16.72cm3, LN: 4.67cm3 vs 4.12cm3). As for the second stage (from the 5th fraction to post-RT), the mean ADC value of GTV and LN continued to increase by 45.58% and 41.2% respectively, while the volumes decreased by 86.07% (GTV) and 61.6% (LN). Multivariate analysis showed the mean ADC changes of GTV from pre-RT to the 5th fraction (ΔADC5) was the only independent prognostic factor for treatment response of NPC. ROC showed that the cut-off value for ΔADC5 was 158.82mm2/s (sensitivity: 87%; specificity: 65%).

Conclusions

Mean ADC values of GTV and LN increased dramatically during RT for NPC patients. The mean ADC began to increase at the 5th fraction, while the change of volume was minimal. Early ADC changes at the 5th fraction might be a new and sensitive biomarker to predict the prognosis for NPC patients independently of volume change.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.